Man Group plc Buys Shares of 119,056 Prestige Consumer Healthcare Inc. $PBH

Man Group plc acquired a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 119,056 shares of the company’s stock, valued at approximately $5,628,000. Man Group plc owned about 0.25% of Prestige Consumer Healthcare as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Jupiter Topco LLC acquired a new stake in Prestige Consumer Healthcare during the 2nd quarter worth approximately $1,068,000. Hsbc Holdings PLC acquired a new stake in Prestige Consumer Healthcare during the 2nd quarter worth about $508,000. Legal & General Group Plc bought a new stake in Prestige Consumer Healthcare in the second quarter worth approximately $5,194,000. The Manufacturers Life Insurance Company bought a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at $31,135,000. Finally, Van Hulzen Asset Management LLC acquired a new position in shares of Prestige Consumer Healthcare during the second quarter valued at about $476,000. Institutional investors own 99.95% of the company’s stock.

Key Headlines Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Attractive value profile: A Zacks comparison of PBH and Stryker (SYK) highlights the value-investing case for Prestige Consumer Healthcare. PBH’s lower earnings multiple and defensive consumer-healthcare portfolio could support investor interest, although the comparison does not guarantee that PBH is the superior investment. PBH vs. SYK: Which Stock Is the Better Value Option?
• Positive Sentiment: Longer-term earnings growth: Zacks Research projects EPS of $4.55 for fiscal 2027, rising to $5.06 in fiscal 2028 and $5.25 in fiscal 2029. The forecasts imply improving earnings power and provide a potential catalyst if the company delivers.
• Neutral Sentiment: Quarterly estimates remain steady: Zacks forecasts EPS of $1.06 for fiscal Q2 2027, $1.22 for Q3 and $1.30 for Q4, followed by estimates of $1.14, $1.19, $1.38 and $1.35 for fiscal 2028’s quarters. These projections indicate expectations for consistent profitability rather than a near-term earnings surprise.
• Negative Sentiment: Analyst stance is cautious: Zacks Research maintains a “Hold” rating, and its fiscal 2027 EPS forecast of $4.55 is essentially in line with the $4.56 consensus estimate. That suggests the expected earnings growth is largely recognized in current expectations, limiting an immediate upgrade catalyst.

Prestige Consumer Healthcare Price Performance

PBH opened at $52.48 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $71.07. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of 14.70, a PEG ratio of 1.64 and a beta of 0.34. The stock’s 50 day simple moving average is $50.22 and its 200 day simple moving average is $54.62.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company had revenue of $265.71 million for the quarter, compared to the consensus estimate of $253.02 million. During the same quarter in the previous year, the business earned $0.90 EPS. Prestige Consumer Healthcare’s revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, analysts predict that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PBH has been the subject of a number of analyst reports. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, August 10th. Finally, Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).